January 02, 2026 06:44 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
New Year horror in Switzerland: Dozens feared dead in Crans-Montana bar explosion | Tobacco stocks crushed as govt slaps fresh excise duty from Feb 1 | Vodafone Idea shares explode 10% after surprise settlement and govt relief boost | No third party involved: India govt sources refute China’s Operation Sindoor ceasefire claim | Amit Shah blasts TMC over border fencing; Mamata fires back on Pahalgam and Delhi blast | 'A profound loss for Bangladesh politics': Sheikh Hasina mourns Khaleda Zia’s death | PM Modi mourns Khaleda Zia’s death, hails her role in India-Bangladesh ties | Bangladesh’s first female Prime Minister Khaleda Zia passes away at 80 | India rejects Pakistan’s Christmas vandalism remarks, cites its ‘abysmal’ minority record | Minority under fire: Hindu houses torched in Bangladesh village
Image: Youtube Screen grab

Saridon, Corex and 326 other combination drugs banned

| @indiablooms | Sep 13, 2018, at 06:47 pm

New Delhi, Sept 13 (IBNS) : The Ministry of Health has banned the production, sale of about 328 fixed dose combinations of drugs (FDCs), including Saridon and Corex, two popular drugs in the country, reports said.

This ban will bring an end to a long legal battle between the ministry and the drug manufacturers. The battle, which has been ongoing since 2016, called for these ‘unsafe’ drugs to be banned.

Around 6,000 drug brands are expected to be affected by this ban, among them popular brands such as Saridon (painkiller), Panderm (skin cream), Lupidiclox (antibiotic), Corex (cough syrup) and several others.

In December 2017, the Supreme Court asked Drugs Technical Advisory Board (DTAB) to intervene in the matter. The DTAB eventually said there was no therapeutic evidence that the ingredients in about 328 of these FDCs cause any harm to people.

The All India Drug Action Network sought the banning of the drugs which were not part of the DTAB report, as these itself accounted for about Rs 2,500 crore of the pharmaceutical market.

 

 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.